Search
Infantile Fibrosarcoma and Other Solid Tumors Respond Well to Precision Medicine
- OPACC
- Dec 24, 2024
- 1 min read
There’s new evidence that Larotrectinib (Vitrakvi), by Loxo Oncology and Bayer, is highly effective in children with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Comentarios